CAS Medical Systems

Founded in 1984, CAS Medical Systems, or CASMED, established itself as a developer of non-invasive patient monitoring devices. The company focused on creating technology to provide accurate, vital measurements to improve patient care, with products like vital signs monitors and specialized neonatal supplies. A key innovation for CASMED was its FORE-SIGHT Cerebral Oximetry technology. This system allowed for the non-invasive monitoring of tissue oxygenation in the brain, a critical metric for clinicians to detect dangerously low oxygen levels and intervene quickly. This technology became a powerful tool in operating rooms and critical care settings, setting the company apart in the medical device market. The company's journey led to a significant milestone in February 2019, when Edwards Lifesciences, a global leader in structural heart disease and critical care monitoring, announced its intention to acquire CASMED. The all-cash deal was valued at approximately $100 million. This acquisition was a strategic move for Edwards, which planned to integrate CASMED's FORE-SIGHT technology into its own HemoSphere advanced monitoring platform. The combination aimed to provide physicians with a more comprehensive view of their patients' status, enhancing decision-making during critical procedures.